» Articles » PMID: 16218083

Validation of a Polysomnographic Score for REM Sleep Behavior Disorder

Overview
Journal Sleep
Specialty Psychiatry
Date 2005 Oct 13
PMID 16218083
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) was described more than 2 decades ago, but only 1 report on 5 patients and 5 normal subjects has tested the effectiveness of a method by which relevant polysomnographic findings can be quantified. We sought to validate this method in a larger sample of patients and control subjects.

Design: Cross-sectional.

Setting: Academic hospital.

Interventions: A clinician interviewed 17 patients at risk for RBD secondary to neurodegenerative disorders and 6 controls to assess whether RBD was present by history. Bed partners completed a questionnaire that quantified RBD symptom severity. From 2 consecutive nocturnal studies in each patient, 2 different polysomnographic RBD scores were generated: the percentage of 30-second REM epochs with at least 15 seconds of tonically maintained electromyographic activity, and the percentage of 3-second REM mini-epochs that contained phasic electromyographic bursts.

Measurements And Results: The tonic and phasic measures, combined together, were higher in patients with clinical determinations of probable or possible RBD (n=9) than in patients judged unlikely to have RBD (n=4, P = .023). The overall polysomnographic measure correlated with the symptom scores (rho = 0.42, P = .048). Specific polysomnographic RBD measures on night 1 correlated highly with those on night 2 (rho > 0.70, P < .0001).

Conclusions: This quantitative method to assess the severity of RBD polysomnographic features appears to be both valid and reliable in patients at risk for RBD because of neurodegenerative disorders.

Citing Articles

Effect of exercise on sleep quality in Parkinson's disease: a mini review.

Shafiq M, Singh J, Khan Z, Neary J, Bardutz H BMC Neurol. 2024; 24(1):49.

PMID: 38291381 PMC: 10826022. DOI: 10.1186/s12883-024-03548-9.


Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium.

Choudhury P, Lee-Iannotti J, Busicescu A, Rangan P, Fantini M, Avidan A Neurology. 2024; 102(3):e208008.

PMID: 38181331 PMC: 11097765. DOI: 10.1212/WNL.0000000000208008.


Ikelos-RWA. Validation of an Automatic Tool to Quantify REM Sleep Without Atonia.

Papakonstantinou A, Klemming J, Haberecht M, Kunz D, Bes F Clin EEG Neurosci. 2023; 55(6):657-664.

PMID: 37192675 PMC: 11459856. DOI: 10.1177/15500594231175320.


Prognostic biomarkers in prodromal α-synucleinopathies: DAT binding and REM sleep without atonia.

Kunz D, Stotz S, de Zeeuw J, Papakonstantinou A, Dumchen S, Haberecht M J Neurol Neurosurg Psychiatry. 2023; 94(7):532-540.

PMID: 36725328 PMC: 10314035. DOI: 10.1136/jnnp-2022-330048.


Behavioral validation of the University of Michigan REM behavior disorder questionnaire in the synucleinopathies.

Dworetz A, Trotti L, Bliwise D J Neurol Sci. 2022; 436:120219.

PMID: 35272234 PMC: 9018590. DOI: 10.1016/j.jns.2022.120219.